Alder BioPharmaceuticals Inc. (NASDAQ:ALDR)’s share price gapped up before the market opened on Thursday . The stock had previously closed at $31.25, but opened at $31.36. Alder BioPharmaceuticals shares last traded at $31.83, with a volume of 347,227 shares changing hands.

Several brokerages have commented on ALDR. Brean Capital began coverage on Alder BioPharmaceuticals in a research report on Wednesday, April 20th. They issued a “buy” rating and a $45.00 price objective on the stock. Wells Fargo & Co. began coverage on Alder BioPharmaceuticals in a research report on Thursday, April 21st. They issued an “outperform” rating on the stock. Zacks Investment Research downgraded Alder BioPharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday, May 3rd. Finally, Jefferies Group reaffirmed a “buy” rating and issued a $61.00 price objective on shares of Alder BioPharmaceuticals in a research report on Thursday, June 9th. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average target price of $47.60.

The firm has a 50 day moving average of $27.15 and a 200 day moving average of $25.34. The stock’s market capitalization is $1.58 billion.

Alder BioPharmaceuticals (NASDAQ:ALDR) last announced its quarterly earnings data on Tuesday, July 26th. The biopharmaceutical company reported ($0.79) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.75) by $0.04. During the same quarter last year, the firm posted ($0.46) EPS. The company earned $0.11 million during the quarter, compared to analysts’ expectations of $1.14 million. The business’s quarterly revenue was up 112900.0% compared to the same quarter last year. On average, equities analysts predict that Alder BioPharmaceuticals Inc. will post ($2.76) earnings per share for the current fiscal year.

In other Alder BioPharmaceuticals news, VP Jeffrey T. L. Smith sold 16,090 shares of the firm’s stock in a transaction on Friday, June 3rd. The stock was sold at an average price of $30.20, for a total transaction of $485,918.00. Following the completion of the sale, the vice president now owns 16,090 shares of the company’s stock, valued at $485,918. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO Randall C. Schatzman sold 10,000 shares of the firm’s stock in a transaction on Tuesday, May 24th. The stock was sold at an average price of $28.02, for a total value of $280,200.00. Following the sale, the chief executive officer now directly owns 115,933 shares of the company’s stock, valued at approximately $3,248,442.66. The disclosure for this sale can be found here.

A number of large investors have bought and sold shares of the company. Pyrrho Capital Management LP boosted its stake in Alder BioPharmaceuticals by 205.0% in the fourth quarter. Pyrrho Capital Management LP now owns 63,000 shares of the biopharmaceutical company’s stock valued at $2,081,000 after buying an additional 42,343 shares during the period. Wells Fargo & Company MN boosted its stake in Alder BioPharmaceuticals by 290.6% in the fourth quarter. Wells Fargo & Company MN now owns 269,774 shares of the biopharmaceutical company’s stock valued at $8,911,000 after buying an additional 200,707 shares during the period. California Public Employees Retirement System boosted its stake in Alder BioPharmaceuticals by 834.5% in the fourth quarter. California Public Employees Retirement System now owns 81,300 shares of the biopharmaceutical company’s stock valued at $2,685,000 after buying an additional 72,600 shares during the period. Nationwide Fund Advisors boosted its stake in Alder BioPharmaceuticals by 103.6% in the fourth quarter. Nationwide Fund Advisors now owns 30,380 shares of the biopharmaceutical company’s stock valued at $1,003,000 after buying an additional 15,457 shares during the period. Finally, Janus Capital Management boosted its stake in Alder BioPharmaceuticals by 391.1% in the third quarter. Janus Capital Management now owns 4,239,855 shares of the biopharmaceutical company’s stock valued at $138,900,000 after buying an additional 3,376,540 shares during the period.

Alder Biopharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company discovers, develops and focuses to commercialize therapeutic antibodies with the potential to transform current treatment paradigms. The Company has developed an antibody platform designed to select antibodies that have the potential to maximize efficacy, as well as speed of onset and durability of therapeutic response.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.